论文部分内容阅读
目的探讨阿托伐他汀联合雷公藤多苷对免疫球蛋白A(Ig A)肾病患者血脂和尿蛋白的影响。方法我院收治的Ig A肾病患者66例随机分为对照组(32例)和试验组(34例),对照组口服雷公藤多苷60 mg·d-1;试验组口服雷公藤多苷60 mg·d-1+阿托伐他汀20 mg·d-1,疗程均为3个月。观察2组患者治疗前后血脂、24 h尿蛋白等指标。结果治疗后,试验组患者总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)较治疗前显著降低(P<0.05);2组治疗后24 h尿蛋白均显著下降,且试验组下降更为显著(P<0.05)。结论阿托伐他汀联合雷公藤多苷可显著降低Ig A肾病患者血脂和24 h尿蛋白水平。
Objective To investigate the effects of atorvastatin combined with tripterygium glycosides on serum lipids and urinary protein in patients with IgA nephropathy. Methods Sixty-six patients with IgA nephropathy admitted to our hospital were randomly divided into control group (32 cases) and trial group (34 cases), and control group received tripterygium glycosides 60 mg · d-1. mg · d-1 + atorvastatin 20 mg · d-1 for 3 months. Two groups of patients before and after treatment of blood lipids, 24 h urinary protein and other indicators. Results After treatment, the total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) ); Urinary protein in 24 hours after treatment in both groups decreased significantly, and the test group decreased more significantly (P <0.05). Conclusion Atorvastatin combined with tripterygium glycosides can significantly reduce the level of serum lipids and 24 h urinary protein in patients with IgA nephropathy.